Grundläggande statistik
| CIK | 1531177 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Sight Sciences, Inc.
SEC Filings (Chronological Order)
Denna sida innehåller en komplett, kronologisk lista över SEC-arkiveringar, exklusive ägande-arkiveringar som vi tillhandahåller på andra ställen.
| August 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 27, 2025 Sight Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40587 80-0625749 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| August 7, 2025 |
Exhibit 99.1 Sight Sciences Reports Second Quarter 2025 Financial Results and Raises Full Year 2025 Revenue Guidance MENLO PARK, Calif., August 7, 2025 (GLOBE NEWSWIRE) - Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40587 SIGHT SCIENCES, INC. |
|
| August 7, 2025 |
Sight Sciences Investor Presentation August 2025 Sight Sciences Investor Presentation August 2025 Forward-Looking Statements This presentation, together with other statements and information publicly disseminated by the Company, contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which statements are subject to considerable risks and uncertainties. |
|
| August 7, 2025 |
FORM 8-K Item 2.02 Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 07, 2025 Sight Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40587 80-0625749 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| June 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2025 Sight Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40587 80-0625749 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 30, 2025 |
Conflict Minerals Report as required by Item 1.01 and 1.02 of this Form SD. Exhibit 1.01 CONFLICT MINERALS REPORT OF SIGHT SCIENCES, INC. FOR THE REPORTING PERIOD FROM JANUARY 1 TO DECEMBER 31, 2024 I. Introduction This is the Conflict Minerals Report1 of Sight Sciences, Inc. (“we,” “our,” “us,” “Sight Sciences,” or the “Company”) prepared for calendar year 2024 in accordance with Rule 13p-1 (“Rule 13p-1”) under the Securities Exchange Act of 1934 (the “Act”). Numerous te |
|
| May 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report SIGHT SCIENCES, INC. (Exact name of the registrant as specified in its charter) Delaware 001-40587 80-0625749 (State or other jurisdiction of (Commission (IRS Employer incorporation or organization) File Number) Identification No.) 4040 Campbell Ave, Suite 100 Menlo Park, CA 94025 (Address |
|
| May 8, 2025 |
FORM 8-K Item 2.02 Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 08, 2025 Sight Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40587 80-0625749 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40587 SIGHT SCIENCES, INC. |
|
| May 8, 2025 |
Sight Sciences Investor Presentation May 2025 Sight Sciences Investor Presentation May 2025 Forward-Looking Statements This presentation, together with other statements and information publicly disseminated by the Company, contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which statements are subject to considerable risks and uncertainties. |
|
| May 8, 2025 |
Exhibit 99.1 Sight Sciences Reports First Quarter 2025 Financial Results and Reaffirms Full Year 2025 Revenue Guidance MENLO PARK, Calif., May 8, 2025 (GLOBE NEWSWIRE) - Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives, today reported financial |
|
| April 23, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 22, 2025 |
Sight Sciences Appoints Gary Burbach to its Board of Directors Exhibit 99.1 Sight Sciences Appoints Gary Burbach to its Board of Directors MENLO PARK, Calif., April 22, 2025 (GLOBE NEWSWIRE) - Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences, or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, announced today that Gerhard (Gary) F. Burbach was ap |
|
| April 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 21, 2025 Sight Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40587 80-0625749 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| March 7, 2025 |
Exhibit 24.1 POWER OF ATTORNEY KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Paul Badawi and Alison Bauerlein, and each of them individually, his and her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him and her and in his and her name, place, and stead, in any and all capac |
|
| March 7, 2025 |
Exhibit 10.13 Employment Agreement This Employment Agreement (this “Agreement”), effective as of November 4, 2024 (the “Effective Date”), is made by and between Sight Sciences, Inc., a Delaware corporation (together with any successor thereto, the “Company”), and Manohar K. Raheja (“Executive”) (collectively referred to herein as the “Parties” or individually referred to as a “Party”). RECITALS A. |
|
| March 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40587 SIGHT SCIENCES, |
|
| March 7, 2025 |
Exhibit 10.12 Employment Agreement This Employment Agreement (this “Agreement”), effective as of November 4, 2024 (the “Effective Date”), is made by and between Sight Sciences, Inc., a Delaware corporation (together with any successor thereto, the “Company”), and Brenton Taylor (“Executive”) (collectively referred to herein as the “Parties” or individually referred to as a “Party”). RECITALS A. It |
|
| March 7, 2025 |
Sight Sciences, Inc. Insider Trading Compliance Policy Exhibit 19.1 Sight Sciences, Inc. Insider Trading Compliance Policy This Insider Trading Compliance Policy (this “Policy”) consists of seven sections: • Section I provides an overview; • Section II sets forth the policies of the Company prohibiting insider trading; • Section III explains insider trading; • Section IV consists of procedures that have been put in place by the Company to prevent insi |
|
| March 7, 2025 |
Sight Sciences, Inc. Non-Employee Director Compensation Program Exhibit 10.4 Sight Sciences, Inc. Non-Employee Director Compensation Program Non-employee members of the board of directors (the “Board”) of Sight Sciences, Inc. (the “Company”) shall receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this “Program”). The cash and equity compensation described in this Program shall be paid or be made, as applicabl |
|
| March 5, 2025 |
INVESTOR PRESENTATION MARCH 2025 INVESTOR PRESENTATION MARCH 2025 Forward-Looking Statements This presentation, together with other statements and information publicly disseminated by the Company, contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which statements are subject to considerable risks and uncertainties. |
|
| March 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 05, 2025 Sight Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40587 80-0625749 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| March 5, 2025 |
Exhibit 99.1 Sight Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Initiates Full Year 2025 Financial Guidance MENLO PARK, Calif., March 5, 2025 (GLOBE NEWSWIRE) - Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard |
|
| January 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 24, 2025 Sight Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40587 80-0625749 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| January 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 14, 2025 Sight Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40587 80-0625749 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| January 14, 2025 |
Exhibit 99.1 Sight Sciences Announces Preliminary, Unaudited Fourth Quarter and Full Year 2024 Financial Highlights MENLO PARK, Calif., January 14, 2025 (GLOBE NEWSWIRE) - Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients' lives, today |
|
| December 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 11, 2024 Sight Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40587 80-0625749 (State or Other Jurisdiction of Incorporation) (Commission |
|
| November 14, 2024 |
LIMITED POWER OF ATTORNEY BANK OF AMERICA CORPORATION EX-99 2 bacpoa.htm BANK OF AMERICA CORPORATION LIMITED POWER OF ATTORNEY BANK OF AMERICA CORPORATION, a Delaware corporation (the "Corporation" ), does hereby make, constitute, and appoint each of Marie Andre, Andres Ortiz Custodio, Kamil Dziedzic, Valerie Ezeagbo, Kelvin Kwo k, Frank Lui, James Todd, Ben Tsoi, Michelle Wong, and Monica Yako as an attorney-in-fact for the Corporation acting for th |
|
| November 14, 2024 |
SGHT / Sight Sciences, Inc. / BANK OF AMERICA CORP /DE/ Passive Investment SC 13G/A 1 doc1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 01)* SIGHT SCIENCES, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 82657M105 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule p |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 01, 2024 Sight Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40587 80-0625749 (State or Other Jurisdiction of Incorporation) (Commission |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40587 SIGHT SCIENCES, INC. |
|
| November 7, 2024 |
Exhibit 99.1 Sight Sciences Reports Third Quarter 2024 Financial Results and Updates its Full Year 2024 Adjusted Operating Expense Guidance MENLO PARK, Calif., November 7, 2024 (GLOBE NEWSWIRE) - Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the st |
|
| November 7, 2024 |
Exhibit 99.3 Sight Sciences Appoints MK Raheja as Executive Vice President, Research and Development and Brenton Taylor as Executive Vice President, Operations New leadership appointments strengthen Sight Sciences’ commitment to advancing innovative eyecare solutions and supporting scalable operations and growth MENLO PARK, Calif., November 7, 2024 (GLOBE NEWSWIRE) - Sight Sciences, Inc. (Nasdaq: |
|
| November 7, 2024 |
INVESTOR PRESENTATION NOVEMBER 2024 INVESTOR PRESENTATION NOVEMBER 2024 Forward-Looking Statements This presentation, together with other statements and information publicly disseminated by the Company, contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which statements are subject to considerable risks and uncertainties. |
|
| October 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 3, 2024 Sight Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40587 80-0625749 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| September 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 26, 2024 Sight Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40587 80-0625749 (State or Other Jurisdiction of Incorporation) (Commission |
|
| August 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40587 SIGHT SCIENCES, INC. |
|
| August 1, 2024 |
Exhibit 99.1 Sight Sciences Reports Second Quarter 2024 Financial Results and Narrows Full Year 2024 Financial Guidance MENLO PARK, Calif., August 1, 2024 (GLOBE NEWSWIRE) - Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today |
|
| August 1, 2024 |
INVESTOR PRESENTATION AUGUST 2024 INVESTOR PRESENTATION AUGUST 2024 Forward-Looking Statements This presentation, together with other statements and information publicly disseminated by the Company, contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which statements are subject to considerable risks and uncertainties. |
|
| August 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 01, 2024 Sight Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40587 80-0625749 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| June 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2024 Sight Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40587 80-0625749 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| June 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report SIGHT SCIENCES, INC. (Exact name of the registrant as specified in its charter) Delaware 001-40587 80-0625749 (State or other jurisdiction of (Commission (IRS Employer incorporation or organization) File Number) Identification No.) 4040 Campbell Ave, Suite 100 Menlo Park, CA 94025 (Address |
|
| June 3, 2024 |
Conflict Minerals Report as required by Item 1.01 and 1.02 of this Form SD. Exhibit 1.01 CONFLICT MINERALS REPORT OF SIGHT SCIENCES, INC. FOR THE REPORTING PERIOD FROM JANUARY 1 TO DECEMBER 31, 2023 I. Introduction This is the Conflict Minerals Report1 of Sight Sciences, Inc. (“we,” “our,” “us,” “Sight Sciences,” or the “Company”) prepared for calendar year 2023 in accordance with Rule 13p-1 (“Rule 13p-1”) under the Securities Exchange Act of 1934 (the “Act”). Numerous te |
|
| May 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 30, 2024 Sight Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40587 80-0625749 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40587 SIGHT SCIENCES, INC. |
|
| May 2, 2024 |
EXHIBIT 99.1 Sight Sciences Reports First Quarter 2024 Financial Results and Reaffirms Full Year 2024 Financial Guidance MENLO PARK, Calif., May 2, 2024 (GLOBE NEWSWIRE) - Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today re |
|
| May 2, 2024 | ||
| May 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 02, 2024 Sight Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40587 80-0625749 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| April 29, 2024 |
Exhibit 99.1 Sight Sciences Announces Successful $34 Million Patent Infringement Verdict Against Alcon and its Hydrus Microstent for Microinvasive Glaucoma Surgery MENLO PARK, Calif. – April 29, 2024 - (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences”), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevat |
|
| April 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 26, 2024 Sight Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40587 80-0625749 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 26, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| March 13, 2024 |
Exhibit 24.1 POWER OF ATTORNEY KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Paul Badawi and Alison Bauerlein, and each of them individually, his and her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him and her and in his and her name, place, and stead, in any and all capac |
|
| March 13, 2024 |
Subsidiaries of Sight Sciences, Inc. Exhibit 21.1 Subsidiaries of Sight Sciences, Inc. Legal Name of Subsidiary Jurisdiction of Organization Sight Sciences UK, Ltd. United Kingdom Sight Sciences GmbH Germany |
|
| March 13, 2024 |
Exhibit 10.14 FIRST AMENDMENT TO MULTI-TENANT SPACE LEASE This First Amendment To Multi-Tenant Space Lease (this "First Amendment"), dated as of December 6, 2023 (the “Reference Date”), is made and entered into by and between Deerfield Campbell LLC, a California limited liability company ("Landlord"), and Sight Sciences, Inc., a Delaware corporation ("Tenant"), with reference to those matters set |
|
| March 13, 2024 |
Sight Sciences, Inc. Policy for Recovery of Erroneously Awarded Compensation Exhibit 97.1 SIGHT SCIENCES, INC. POLICY FOR RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION Sight Sciences, Inc. (the “Company”) has adopted this Policy for Recovery of Erroneously Awarded Compensation (the “Policy”), effective as of October 2, 2023 (the “Effective Date”). Capitalized terms used in this Policy but not otherwise defined herein are defined in Section 11. 1. Persons Subject to Policy T |
|
| March 13, 2024 |
Exhibit 4.3 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED The following description of the capital stock of Sight Sciences, Inc. (the “Company”, “we”, “us”, and “our”) and certain provisions of our restated certificate of incorporation (the “Charter”) and restated bylaws (the “Bylaws”) is not intended to be a complet |
|
| March 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40587 SIGHT SCIENCES, |
|
| March 7, 2024 |
Investor Presentation March 2024 Investor Presentation March 2024 Forward-Looking Statements This presentation, together with other statements and information publicly disseminated by the Company, contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which statements are subject to considerable risks and uncertainties. |
|
| March 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 07, 2024 Sight Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40587 80-0625749 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| March 7, 2024 |
Exhibit 99.1 Sight Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Initiates Full Year 2024 Financial Guidance MENLO PARK, Calif., March 7, 2024 (GLOBE NEWSWIRE) - Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care |
|
| February 14, 2024 |
SGHT / Sight Sciences, Inc. / KCK LTD. - SC 13G/A Passive Investment SC 13G/A 1 d642727dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Sight Sciences, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 82657M105 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Chec |
|
| February 13, 2024 |
SGHT / Sight Sciences, Inc. / BANK OF AMERICA CORP /DE/ Passive Investment SC 13G 1 doc1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. N/A)* Sight Sciences, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 82657M105 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursu |
|
| February 13, 2024 |
BANK OF AMERICA CORPORATION LIMITED POWER OF ATTORNEY EX-99 2 bacpoa.htm BANK OF AMERICA CORPORATION LIMITED POWER OF ATTORNEY BANK OF AMERICA CORPORATION, a Delaware corporation (the "Corporation"), does hereby make, constitute, and appoint each of Szabina Biro, Hannah Chae, Andres Ortiz Custodio, Kamil Dziedzic, Krishnan Harihanran, Kelvin Kwok, Frank Lui, James Todd, Michelle Wong, and Monica Yako as an attorney-in-fact for the Corporation acting |
|
| February 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 30, 2024 Sight Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40587 80-0625749 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| January 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 22, 2024 Sight Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40587 80-0625749 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| January 23, 2024 |
Exhibit 4.1 THIS WARRANT AND THE SHARES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR ANY STATE SECURITIES LAWS, AND MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR, SUBJECT TO SECTION 11 HEREOF, AN OPINION OF COUNSEL (WHICH MAY BE COMPANY COUNS |
|
| January 23, 2024 |
Exhibit 99.1 Sight Sciences Announces the Closing of up to $65 Million Senior Secured Credit Facility with Hercules Capital Refinancing replaces prior senior credit facility MENLO PARK, Calif. - January 23, 2024 - (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences”), an eyecare technology company focused on developing and commercializing innovative technology intended to trans |
|
| January 23, 2024 |
Exhibit 10.1 CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE REGISTRANT HAS DETERMINED THAT IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT is made and dated as of January 22, 2024 and is entered into by and among SIGHT SCIENCES |
|
| January 10, 2024 |
SGHT / Sight Sciences, Inc. / D1 Capital Partners L.P. - SIGHT SCIENCES, INC. Passive Investment SC 13G/A 1 p24-0016sc13ga.htm SIGHT SCIENCES, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Sight Sciences, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 82657M105 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the approp |
|
| December 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2023 Sight Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40587 80-0625749 (State or Other Jurisdiction of Incorporation) (Commission |
|
| December 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 7, 2023 Sight Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40587 80-0625749 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| December 1, 2023 |
EX-99.A 2 d621936dex99a.htm EX-99.A CUSIP No. 82657M105 13D Page 10 of 10 Pages EXHIBIT A Agreement of Joint Filing The undersigned hereby agree that a single Schedule 13D (or any amendment thereto) relating to the Common Stock of Sight Sciences, Inc. shall be filed on behalf of each of the undersigned and that this Agreement shall be filed as an exhibit to such Schedule 13D. Date: December 1, 202 |
|
| December 1, 2023 |
SGHT / Sight Sciences Inc / Encrantz Staffan - SC 13D/A Activist Investment SC 13D/A 1 d621936dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2) Sight Sciences, Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 82657M105 (CUSIP Number) Staffan Encrantz Allegro Investment Inc. 525 Middlefield Road, Suite 220 Menlo Park, CA 940 |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2023 Sight Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40587 80-0625749 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| November 7, 2023 |
Investor Presentation November 2023 Investor Presentation November 2023 Forward-Looking Statements This presentation, together with other statements and information publicly disseminated by the Company, contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which statements are subject to considerable risks and uncertainties. |
|
| November 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 07, 2023 Sight Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40587 80-0625749 (State or Other Jurisdiction of Incorporation) (Commission |
|
| November 7, 2023 |
Exhibit 10.3 Fourth aMENDMENT to AMENDED AND RESTATED CREDIT AND SECURITY AGREEMENT (term LOAN) This FOURTH AMENDMENT TO AMENDED AND RESTATED CREDIT AND SECURITY AGREEMENT (TERM LOAN) (this “Agreement”) is made as of this 6th day of November, 2023 (“Effective Date”), by and among SIGHT SCIENCES, INC., a Delaware corporation (“Borrower”), MIDCAP FINANCIAL TRUST, as Agent for Lenders (in such capaci |
|
| November 7, 2023 |
Employment Agreement between Sight Sciences, Inc. and Matthew Link, dated September 11, 2023 Exhibit 10.2 Employment Agreement This Employment Agreement (this “Agreement”), effective as of September 11, 2023 (the “Effective Date”), is made by and between Sight Sciences, Inc., a Delaware corporation (together with any successor thereto, the “Company”), and Matthew Link (“Executive”) (collectively referred to herein as the “Parties” or individually referred to as a “Party”). RECITALS A. It |
|
| November 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40587 SIGHT SCIENCES, INC. |
|
| November 7, 2023 |
Exhibit 99.1 Sight Sciences Reports Third Quarter 2023 Financial Results and Withdraws Guidance for Full Year 2023 MENLO PARK, Calif., November 7, 2023 (GLOBE NEWSWIRE) - Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients' lives, today |
|
| October 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 26, 2023 Sight Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40587 80-0625749 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| October 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 17, 2023 Sight Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40587 80-0625749 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| September 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 20, 2023 Sight Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40587 80-0625749 (State or Other Jurisdiction of Incorporation) (Commission |
|
| September 11, 2023 |
EX-99.2 Exhibit 99.2 Sight Sciences Provides Revenue Guidance For the Third Quarter of 2023 and Updates Revenue Guidance For Full Year 2023 MENLO PARK, Calif., September 11, 2023 (GLOBE NEWSWIRE) – Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and imp |
|
| September 11, 2023 |
EX-99.1 Exhibit 99.1 Sight Sciences Appoints Matt Link as Chief Commercial Officer Former NuVasive President helped scale high-growth medical device company to over $1 billion in revenue MENLO PARK, Calif. - September 11, 2023 - (GLOBE NEWSWIRE) – Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on developing and commercializing innova |
|
| September 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 11, 2023 Sight Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40587 80-0625749 (State or Other Jurisdiction of Incorporation) (Commission |
|
| August 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40587 SIGHT SCIENCES, INC. |
|
| August 3, 2023 |
Sight Sciences Reports Second Quarter 2023 Financial Results and Reaffirms Guidance for Full Year 2023 MENLO PARK, Calif. |
|
| August 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 03, 2023 Sight Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40587 80-0625749 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| August 3, 2023 |
Delivering the Power of Sight Investor Presentation August 2023 Delivering the Power of Sight Investor Presentation August 2023 Forward-Looking Statements This presentation, together with other statements and information publicly disseminated by the Company, contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which statements are subject to considerable risks and uncertainties. |
|
| June 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2023 Sight Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40587 80-0625749 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| June 9, 2023 |
Regulation FD Disclosure, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2023 Sight Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40587 80-0625749 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| June 2, 2023 |
Regulation FD Disclosure, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2023 Sight Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40587 80-0625749 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 31, 2023 |
Conflict Minerals Report as required by Item 1.01 and 1.02 of this Form SD. Exhibit 1.01 CONFLICT MINERALS REPORT OF SIGHT SCIENCES, INC. FOR THE REPORTING PERIOD FROM JANUARY 1 TO DECEMBER 31, 2022 I. Introduction This is the Conflict Minerals Report of Sight Sciences, Inc. (“we,” “our,” “us,” “Sight Sciences,” or the “Company”) prepared for calendar year 2022 in accordance with Rule 13p-1 (“Rule 13p-1”) under the Securities Exchange Act of 1934 (the “Act”). Numerous ter |
|
| May 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report SIGHT SCIENCES, INC. (Exact name of the registrant as specified in its charter) Delaware 001-40587 80-0625749 (State or other jurisdiction of (Commission (IRS Employer incorporation or organization) File Number) Identification No.) 4040 Campbell Ave, Suite 100 Menlo Park, CA 94025 (Address |
|
| May 22, 2023 |
As filed with the Securities and Exchange Commission on May 22, 2023 S-3/A As filed with the Securities and Exchange Commission on May 22, 2023 Registration No. |
|
| May 22, 2023 |
Sight Sciences, Inc. 4040 Campbell Ave, Suite 100 Menlo Park, CA 94025 May 22, 2023 CORRESP Sight Sciences, Inc. 4040 Campbell Ave, Suite 100 Menlo Park, CA 94025 May 22, 2023 SUBMITTED VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Ms. Jessica Ansart Re: Sight Sciences, Inc. Acceleration Request Registration Statement on Form S-3 File No. 333-270629 Requested Date: May 24, 2023 Requested Time: 5:0 |
|
| May 8, 2023 |
Delivering the Power of Sight Investor Presentation May 2023 ® ™ Delivering the Power of Sight Investor Presentation May 2023 ® ™ Forward-Looking Statements This presentation, together with other statements and information publicly disseminated by the Company, contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which statements are subject to considerable risks and uncertainties. |
|
| May 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 08, 2023 Sight Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40587 80-0625749 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 8, 2023 |
Employment Agreement between Sight Sciences, Inc. and Alison Bauerlein, dated April 3, 2023 Exhibit 10.1 Employment Agreement This Employment Agreement (this “Agreement”), effective as of April 3, 2023 (the “Effective Date”), is made by and between Sight Sciences, Inc., a Delaware corporation (together with any successor thereto, the “Company”), and Alison Bauerlein (“Executive”) (collectively referred to herein as the “Parties” or individually referred to as a “Party”). RECITALS A. It i |
|
| May 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40587 SIGHT SCIENCES, INC. |
|
| May 4, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 04, 2023 Sight Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40587 80-0625749 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 4, 2023 |
Exhibit 99.1 Sight Sciences Reports First Quarter 2023 Financial Results and Reaffirms Guidance for Full Year 2023 MENLO PARK, Calif., May 4, 2023 (GLOBE NEWSWIRE) - Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, today reported financial results |
|
| April 26, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 3, 2023 |
Delivering the Power of Sight Investor Presentation April 2023 ™ Delivering the Power of Sight Investor Presentation April 2023 ™ 1 Forward-Looking Statements This press release, together with other statements and information publicly disseminated by the Company, contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which statements are subject to considerable risks and uncertainties. |
|
| April 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 03, 2023 Sight Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40587 80-0625749 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| April 3, 2023 |
Sight Sciences Appoints Ali Bauerlein as Chief Financial Officer Exhibit 99.1 Sight Sciences Appoints Ali Bauerlein as Chief Financial Officer MENLO PARK, Calif. - April 3, 2023 - (GLOBE NEWSWIRE) - Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, today announces the appointment of Alison “Ali” Bauerlein as its C |
|
| March 16, 2023 |
Exhibit 10.20 FOURTH aMENDMENT to AMENDED AND RESTATED CREDIT AND SECURITY AGREEMENT (REVOLVING LOAN) This FOURTH AMENDMENT TO AMENDED AND RESTATED CREDIT AND SECURITY AGREEMENT (REVOLVING LOAN) (this “Agreement”) is made as of this 28th day of December, 2022 (“Effective Date”), by and among SIGHT SCIENCES, INC., a Delaware corporation (“Borrower”), MIDCAP FUNDING IV TRUST, as Agent for Lenders (i |
|
| March 16, 2023 |
EXHIBIT 4.3 SIGHT SCIENCES, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 20 Debt Securities TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee’s Certificate 7 Sectio |
|
| March 16, 2023 |
Powers of Attorney (incorporated by reference to the signature page hereto). S-3 Table of Contents As filed with the Securities and Exchange Commission on March 16, 2023 Registration No. |
|
| March 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40587 SIGHT SCIENCES, |
|
| March 16, 2023 |
Subsidiaries of Sight Sciences, Inc. Exhibit 21.1 Subsidiaries of Sight Sciences, Inc. Legal Name of Subsidiary Jurisdiction of Organization Sight Sciences UK, Ltd. United Kingdom Sight Sciences GmbH Germany |
|
| March 16, 2023 |
As filed with the Securities and Exchange Commission on March 16, 2023 S-8 As filed with the Securities and Exchange Commission on March 16, 2023 Registration No. |
|
| March 16, 2023 |
Exhibit 24.1 POWER OF ATTORNEY KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Paul Badawi and Jim Rodberg, and each of them individually, his and her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him and her and in his and her name, place, and stead, in any and all capacities |
|
| March 16, 2023 |
Exhibit 4.3 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED The following description of the capital stock of Sight Sciences, Inc. (the “Company”, “we”, “us”, and “our”) and certain provisions of our restated certificate of incorporation (the “Charter”) and restated bylaws (the “Bylaws”) is not intended to be a complet |
|
| March 16, 2023 |
EX-FILING FEES Exhibit 107.1 Calculation of Filing Fee Table Form S-8 (Form Type) Sight Sciences, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stoc |
|
| March 16, 2023 |
Exhibit 10.15 Third aMENDMENT to AMENDED AND RESTATED CREDIT AND SECURITY AGREEMENT (term LOAN) This THIRD AMENDMENT TO AMENDED AND RESTATED CREDIT AND SECURITY AGREEMENT (TERM LOAN) (this “Agreement”) is made as of this 28th day of December, 2022 (“Effective Date”), by and among SIGHT SCIENCES, INC., a Delaware corporation (“Borrower”), MIDCAP FINANCIAL TRUST, as Agent for Lenders (in such capaci |
|
| March 16, 2023 |
Employment Agreement between Sight Sciences, Inc. and Jeremy Hayden, dated July 7, 2021 Exhibit 10.10 Employment Agreement This Employment Agreement (this “Agreement”), dated as of July 7, 2021, is made by and between Sight Sciences, Inc., a Delaware corporation (together with any successor thereto, the “Company”), and Jeremy Hayden (“Executive”) (collectively referred to herein as the “Parties” or individually referred to as a “Party”), and will become effective, if at all, upon the |
|
| March 16, 2023 |
EX-FILING FEES Exhibit 107.1 Calculation of Filing Fee Tables Form S-3 (Form Type) Sight Sciences, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount o |
|
| March 13, 2023 |
Exhibit 99.1 Sight Sciences Reports Fourth Quarter and Full Year 2022 Financial Results MENLO PARK, Calif., March 13, 2023 (GLOBE NEWSWIRE) - Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, today reported financial results for the fourth quarter a |
|
| March 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2023 Sight Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40587 80-0625749 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| February 14, 2023 |
SGHT / Sight Sciences, Inc. / HEP Partners LLC - SC 13G/A Passive Investment SC 13G/A 1 d417146dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Sight Sciences, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 82657M105 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check |
|
| February 14, 2023 |
SGHT / Sight Sciences, Inc. / Badawi Paul - SC 13G/A Passive Investment SC 13G/A 1 d412718dsc13ga.htm SC 13G/A Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G/A (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Sight Sciences, Inc. (Name of Issuer) Common Stock (Title of Class of Se |
|
| February 13, 2023 |
SGHT / Sight Sciences, Inc. / KCK LTD. - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Sight Sciences, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 82657M105 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate |
|
| January 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 05, 2023 Sight Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40587 80-0625749 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| January 9, 2023 |
Sight Sciences Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Financial Results Exhibit 99.1 Sight Sciences Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Financial Results Company Also Announces CFO Transition MENLO PARK, Calif.— January 9, 2023— Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, today announc |
|
| January 9, 2023 |
Delivering the Power of Sight Investor Presentation January 2023 ™ EX-99.2 3 sght-ex992.htm EX-99.2 Delivering the Power of Sight Investor Presentation January 2023 ™ 1 Forward-Looking Statements This press release, together with other statements and information publicly disseminated by the Company, contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Ac |
|
| November 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2022 Sight Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40587 80-0625749 (State or Other Jurisdiction of Incorporation) (Commission |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40587 SIGHT SCIENCES, INC. |
|
| November 10, 2022 |
Exhibit 10.1 Certain information marked as [****] has been excluded from this exhibit because it is both (i) not material and (ii) is the type that the Registrant treats as private or confidential. AMENDMENT #2 TO SUPPLY AGREEMENT This Amendment #2 to Supply Agreement (?Amendment?) is made effective as of July 19, 2022 (the ?Amendment Effective Date?) and entered into by and between Sight Sciences |
|
| November 10, 2022 |
Exhibit 99.1 Sight Sciences Reports Third Quarter 2022 Financial Results MENLO PARK, Calif., November 10, 2022 (GLOBE NEWSWIRE) - Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients? lives, today reported financial results for the third quarter ended September 30, 2022. Recent Business Highlight |
|
| August 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 23, 2022 Sight Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40587 80-0625749 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| August 23, 2022 |
Delivering the Power of Sight Investor Presentation August 2022 ™ Delivering the Power of Sight Investor Presentation August 2022 ? 1 Forward Looking Statements This presentation, together with other statements and information publicly disseminated by the Company, contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. |
|
| August 23, 2022 |
Exhibit 99.1 Sight Sciences Introduces the SION? Surgical Instrument ? The First Bladeless Device Used in Goniotomy Featuring bladeless technology, SION is designed to facilitate a smooth, gentle goniotomy procedure MENLO PARK, Calif., August 23, 2022 (GLOBE NEWSWIRE) - Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on developing and commercializing innovative solutions |
|
| August 11, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2022 Sight Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40587 80-0625749 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| August 11, 2022 |
Exhibit 99.1 Sight Sciences Reports Second Quarter 2022 Financial Results MENLO PARK, Calif., August 11, 2022 (GLOBE NEWSWIRE) - Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients? lives, today reported financial results for the second quarter ended June 30, 2022. Recent Business Highlights ? G |
|
| August 11, 2022 |
Exhibit 10.1 THIRD aMENDMENT to AMENDED AND RESTATED CREDIT AND SECURITY AGREEMENT (REVOLVING LOAN) This THIRD AMENDMENT TO AMENDED AND RESTATED CREDIT AND SECURITY AGREEMENT (REVOLVING LOAN) (this ?Agreement?) is made as of this 10th day of May, 2022 (?Effective Date?), by and among SIGHT SCIENCES, INC., a Delaware corporation (?Borrower?), MIDCAP FUNDING IV TRUST, as Agent for Lenders (in such c |
|
| August 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40587 SIGHT SCIENCES, INC. |
|
| July 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 15, 2022 Sight Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40587 80-0625749 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| June 10, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2022 Sight Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40587 80-0625749 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 19, 2022 |
CUSIP No. 82657M105 13D Page 11 of 11 Pages EXHIBIT A Agreement of Joint Filing The undersigned hereby agree that a single Schedule 13D (or any amendment thereto) relating to the Common Stock of Sight Sciences, Inc. shall be filed on behalf of each of the undersigned and that this Agreement shall be filed as an exhibit to such Schedule 13D. Date: May 19, 2022 Allegro Investment Fund, L.P. By: /s/ |
|
| May 19, 2022 |
SGHT / Sight Sciences, Inc. / Encrantz Staffan - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1) Sight Sciences, Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 82657M105 (CUSIP Number) Staffan Encrantz Allegro Investment Inc. 525 Middlefield Road, Suite 220 Menlo Park, CA 94025 (650) 323-8300 (Name, Address and Te |
|
| May 10, 2022 |
Delivering the Power of Sight Investor Presentation May 2022 ™ Delivering the Power of Sight Investor Presentation May 2022 ? 1 Forward Looking Statements This presentation, together with other statements and information publicly disseminated by the Company, contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. |
|
| May 10, 2022 |
Exhibit 99.1 Sight Sciences Reports First Quarter 2022 Financial Results MENLO PARK, Calif., May 10, 2022 (GLOBE NEWSWIRE) - Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients? lives, today reported financial results for the quarter ended March 31, 2022. Recent Business Highlights ? Generated f |
|
| May 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2022 Sight Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40587 80-0625749 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40587 SIGHT SCIENCES, INC. |
|
| May 10, 2022 |
Exhibit 10.1 SIGHT SCIENCES, INC. 2021 INCENTIVE AWARD PLAN Sub-Plan for UK EMPLOYEES a. Purpose Pursuant to the powers granted by the Administrator in Section 10.5 of the Sight Sciences, Inc. 2021 Incentive Award Plan (as it may be amended or restated from time to time, the ?Plan?), the Administrator has adopted this Sub-Plan (the ?Sub-Plan?). The purpose of the Sub-Plan is to promote the success |
|
| April 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 29, 2022 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 18, 2022 Sight Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40587 80-0625749 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| April 18, 2022 |
SGHT / Sight Sciences, Inc. / SHD GP II, LLC Activist Investment SC 13D/A 1 scientifichealth13da.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Sight Sciences, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 82657M105 (CUSIP Number) Andrew Offer Chief Executive Officer SHD Management, LLC 2305 Cedar Springs, Suite #240 Dallas, Texas 752 |
|
| March 24, 2022 |
Exhibit 10.13 Second aMENDMENT to AMENDED AND RESTATED CREDIT AND SECURITY AGREEMENT (REVOLVING LOAN) This SECOND AMENDMENT TO AMENDED AND RESTATED CREDIT AND SECURITY AGREEMENT (REVOLVING LOAN) (this ?Agreement?) is made as of this 15th day of November, 2021 (?Effective Date?), by and among SIGHT SCIENCES, INC., a Delaware corporation (?Borrower?), MIDCAP FUNDING IV TRUST, as Agent for Lenders (i |
|
| March 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40587 SIGHT SCIENCES, |
|
| March 24, 2022 |
Exhibit 10.14 Second aMENDMENT to AMENDED AND RESTATED CREDIT AND SECURITY AGREEMENT (term LOAN) This SECOND AMENDMENT TO AMENDED AND RESTATED CREDIT AND SECURITY AGREEMENT (TERM LOAN) (this ?Agreement?) is made as of this 15th day of October, 2021 (?Effective Date?), by and among SIGHT SCIENCES, INC., a Delaware corporation (?Borrower?), MIDCAP FINANCIAL TRUST, as Agent for Lenders (in such capac |
|
| March 24, 2022 |
Exhibit 99.1 Sight Sciences Reports Fourth Quarter and Full Year 2021 Financial Results MENLO PARK, Calif., March 24, 2022 (GLOBE NEWSWIRE) - Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of care and improve patients? lives, today reported financial results for the quarter and year ended December 31, 2021 |
|
| March 24, 2022 |
Delivering the Power of Sight Investor Presentation March 2022 ™ Delivering the Power of Sight Investor Presentation March 2022 ? 1 Forward Looking Statements This presentation, together with other statements and information publicly disseminated by the Company, contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. |
|
| March 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 24, 2022 Sight Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40587 80-0625749 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| March 24, 2022 |
Subsidiaries of Sight Sciences, Inc. Exhibit 21.1 Subsidiaries of Sight Sciences, Inc. Legal Name of Subsidiary Jurisdiction of Organization Sight Sciences UK, Ltd. United Kingdom Sight Sciences GmbH Germany |
|
| March 24, 2022 |
Exhibit 4.4 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED The following description of the capital stock of Sight Sciences, Inc. (the ?Company?, ?we?, ?us?, and ?our?) and certain provisions of our restated certificate of incorporation (the ?Charter?) and restated bylaws (the ?Bylaws?) is not intended to be a complet |
|
| March 24, 2022 |
Exhibit 10.15 Certain information marked as [****] has been excluded from this exhibit because it is both (i) not material and (ii) is the type that the Registrant treats as private or confidential. AMENDMENT #1 TO SUPPLY AGREEMENT This Amendment #1 to Supply Agreement (?Amendment?) is made effective as of January 28, 2022 (the ?Amendment Effective Date?) and entered into by and between Sight Scie |
|
| March 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2022 Sight Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40587 80-0625749 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| March 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2022 Sight Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40587 80-0625749 (State or Other Jurisdiction of Incorporation) (Commission |
|
| February 14, 2022 |
SGHT / Sight Sciences, Inc. / Badawi Paul - SC 13G Passive Investment Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to ? 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to ? 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Sight Sciences, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 82657M105 (CUSIP Number) Decembe |
|
| February 14, 2022 |
SGHT / Sight Sciences, Inc. / HEP Partners LLC - SC 13G Passive Investment SC 13G 1 d274071dsc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Sight Sciences, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 82657M105 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the ap |
|
| February 14, 2022 |
SGHT / Sight Sciences, Inc. / Selnick Jesse - SC 13G Passive Investment Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to ? 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to ? 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Sight Sciences, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 82657M105 (CUSIP Number) Decembe |
|
| February 14, 2022 |
JOINT FILING AGREEMENT February 14, 2022 Exhibit 99.1 JOINT FILING AGREEMENT February 14, 2022 Pursuant to and in accordance with the Securities Exchange Act of 1934, as amended (the ?Act?), and the rules and regulations thereunder, each party hereto hereby agrees to the joint filing, on behalf of each of them, of any filing required by such party under Section 13 or Section 16 of the Act or any rule or regulation thereunder (including a |
|
| January 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2022 Sight Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40587 80-0625749 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| January 10, 2022 |
Sight Sciences Announces Preliminary Unaudited Fourth Quarter and Full Year 2021 Financial Results Exhibit 99.1 Sight Sciences Announces Preliminary Unaudited Fourth Quarter and Full Year 2021 Financial Results MENLO PARK, Calif., January 10, 2022 (GLOBE NEWSWIRE) ? Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of care and improve patients? lives, today announced preliminary unaudited financial results |
|
| December 10, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 10, 2021 Sight Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40587 80-0625749 (State or Other Jurisdiction of Incorporation) (Commission |
|
| December 10, 2021 |
Delivering the Power of Sight Investor Presentation December 2021 ? Exhibit 99.1 1 Forward Looking Statements This presentation, together with other statements and information publicly disseminated by the Company, contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amende |
|
| December 10, 2021 |
SGHT / Sight Sciences, Inc. / Encrantz Staffan - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. ) Sight Sciences, Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 82657M105 (CUSIP Number) Staffan Encrantz Allegro Investment Inc. 525 Middlefield Road, Suite 220 Menlo Park, CA 94025 (650) 323-8300 (Name, Address and Tel |
|
| November 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2021 Sight Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40587 80-0625749 (State or Other Jurisdiction of Incorporation) (Commission |
|
| November 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40587 SIGHT SCIENCES, INC. |
|
| November 10, 2021 |
Sight Sciences Reports Third Quarter 2021 Financial Results MENLO PARK, Calif., November 10, 2021 (GLOBE NEWSWIRE) - Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of care and improve patients? lives, today reported financial results for the quarter ended September 30, 2021. Recent Business Highlights ? Ge |
|
| November 10, 2021 |
Execution Version Exhibit 10.1 FIRST aMENDMENT TO AMENDED AND RESTATED CREDIT AND SECURITY AGREEMENT (REVOLVING LOAN) This FIRST AMENDMENT TO AMENDED AND RESTATED CREDIT AND SECURITY AGREEMENT (REVOLVING LOAN) (this ?Agreement?) is made as of this 5th day of October, 2021 (?Effective Date?), by and among SIGHT SCIENCES, INC., a Delaware corporation (?Borrower?), MIDCAP FUNDING IV TRUST, as Agent f |
|
| November 10, 2021 |
Execution Version Exhibit 10.2 FIRST aMENDMENT TO AMENDED AND RESTATED CREDIT AND SECURITY AGREEMENT (term LOAN) This FIRST AMENDMENT TO AMENDED AND RESTATED CREDIT AND SECURITY AGREEMENT (TERM LOAN) (this ?Agreement?) is made as of this 5th day of October, 2021 (?Effective Date?), by and among SIGHT SCIENCES, INC., a Delaware corporation (?Borrower?), MIDCAP FINANCIAL TRUST, as Agent for Lenders |
|
| November 10, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2021 Sight Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40587 80-0625749 (State or Other Jurisdiction of Incorporation) (Commission |
|
| September 9, 2021 |
Delivering the Power of Sight Investor Presentation September 2021 ™ Delivering the Power of Sight Investor Presentation September 2021 ? 1 Forward Looking Statements This presentation, together with other statements and information publicly disseminated by the Company, contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. |
|
| September 9, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 09, 2021 Sight Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40587 80-0625749 (State or Other Jurisdiction of Incorporation) (Commission |
|
| August 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40587 SIGHT SCIENCES, INC. |
|
| August 12, 2021 |
Sight Sciences Reports Second Quarter 2021 Financial Results Exhibit 99.1 Sight Sciences Reports Second Quarter 2021 Financial Results MENLO PARK, Calif., August 12, 2021 (GLOBE NEWSWIRE) - Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of care and improve patients? lives, today reported financial results for the quarter ended June 30, 2021. Recent Business Highligh |
|
| August 12, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2021 Sight Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40587 80-0625749 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| August 10, 2021 |
SGHT / Sight Sciences, Inc. / D1 Capital Partners L.P. - SIGHT SCIENCES, INC. Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Sight Sciences, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 82657M105 (CUSIP Number) July 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sch |
|
| July 27, 2021 |
SGHT / Sight Sciences, Inc. / SHD GP II, LLC - SCHEDULE 13D Activist Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Sight Sciences, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 82657M105 (CUSIP Number) Andrew Offer Chief Executive Officer SHD Management, LLC 2305 Cedar Springs, Suite #240 Dallas, Texas 75201 (214) 303-1540 (Name, Address and Te |
|
| July 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 19, 2021 Sight Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40587 80-0625749 (State or other jurisdiction of incorporation or organization) |
|
| July 19, 2021 |
Amended and Restated Bylaws of Sight Sciences, Inc. Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF SIGHT SCIENCES, INC. (a Delaware corporation) TABLE OF CONTENTS Page ARTICLE I - CORPORATE OFFICES 1 1.1 REGISTERED OFFICE 1 1.2 OTHER OFFICES 1 ARTICLE II - MEETINGS OF STOCKHOLDERS 1 2.1 PLACE OF MEETINGS 1 2.2 ANNUAL MEETING 1 2.3 SPECIAL MEETING 1 2.4 ADVANCE NOTICE PROCEDURES FOR BUSINESS BROUGHT BEFORE A MEETING 2 2.5 ADVANCE NOTICE PROCEDURES FOR N |
|
| July 19, 2021 |
Restated Certificate of Incorporation of Sight Sciences, Inc. Exhibit 3.1 RESTATED CERTIFICATE OF INCORPORATION OF SIGHT SCIENCES, INC. The name of the corporation is Sight Sciences, Inc. The corporation was originally incorporated by the filing of its original Certificate of Incorporation with the Secretary of State of the State of Delaware on February 10, 2010. This Restated Certificate of Incorporation of the corporation, which restates and integrates and |
|
| July 16, 2021 |
As filed with the Securities and Exchange Commission on July 15, 2021 As filed with the Securities and Exchange Commission on July 15, 2021 Registration No. |
|
| July 16, 2021 |
Exhibit 4.3 RESTATED CERTIFICATE OF INCORPORATION OF SIGHT SCIENCES, INC. The name of the corporation is Sight Sciences, Inc. The corporation was originally incorporated by the filing of its original Certificate of Incorporation with the Secretary of State of the State of Delaware on February 10, 2010. This Restated Certificate of Incorporation of the corporation, which restates and integrates and |
|
| July 15, 2021 |
10,000,000 Shares Common Stock Table of Contents Filed Pursuant to Rule 424(b)(4) Registration No. 333-257320 PROSPECTUS 10,000,000 Shares Common Stock This is Sight Sciences, Inc.?s initial public offering. We are offering 10,000,000 shares of our common stock. Prior to this offering, there has been no public market for our common stock. The initial public offering price of our common stock is $24 per share. Our common stock h |
|
| July 14, 2021 |
As filed with the Securities and Exchange Commission on July 14, 2021 S-1/A Table of Contents As filed with the Securities and Exchange Commission on July 14, 2021 Registration No. |
|
| July 12, 2021 |
Morgan Stanley & Co. LLC 1585 Broadway New York, New York 10036 BofA Securities Inc. One Bryant Park New York, New York 10036 Citigroup Global Markets Inc. 388 Greenwich Street New York, New York 10013 Piper Sandler & Co. U.S. Bancorp Center 800 Nicollet Mall Minneapolis, Minnesota 55402 July 12, 2021 Securities and Exchange Commission Division of Corporation Finance Office of Manufacturing 100 F |
|
| July 12, 2021 |
July 12, 2021 Via EDGAR Transmission Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| July 8, 2021 |
Form of Indemnification Agreement for Directors and Officers Exhibit 10.5 SIGHT SCIENCES, INC. INDEMNIFICATION AGREEMENT THIS INDEMNIFICATION AGREEMENT (the ?Agreement?) is made and entered into as of July , 2021 between Sight Sciences, Inc., a Delaware corporation (the ?Company?), and [Name] (?Indemnitee?). WITNESSETH THAT: WHEREAS, highly competent persons have become more reluctant to serve corporations as directors, officers or in other capacities unles |
|
| July 8, 2021 |
Employment Agreement between Sight Sciences, Inc. and Shawn O'Neil, date July 7, 2021 Exhibit 10.12 Employment Agreement This Employment Agreement (this ?Agreement?), dated as of July 7, 2021, is made by and between Sight Sciences, Inc., a Delaware corporation (together with any successor thereto, the ?Company?), and Shawn O?Neil (?Executive?) (collectively referred to herein as the ?Parties? or individually referred to as a ?Party?), and will become effective, if at all, upon the |
|
| July 8, 2021 |
Exhibit 1.1 [?] Shares SIGHT SCIENCES, INC. COMMON STOCK (PAR VALUE $0.001 PER SHARE) UNDERWRITING AGREEMENT [?], 2021 [?], 2021 Morgan Stanley & Co. LLC BofA Securities Inc. Citigroup Global Markets Inc. Piper Sandler & Co. c/o Morgan Stanley & Co. LLC 1585 Broadway New York, New York 10036 c/o BofA Securities, Inc. One Bryant Park New York, New York 10036 c/o Citigroup Global Markets Inc. 388 Gr |
|
| July 8, 2021 |
Certificate of Incorporation of the Registrant, as amended (currently in effect) Exhibit 3.1 State of Delaware Secretary of State Division of Corporations Delivered 08:08 AM 11/23/2020 FILED 08:08 AM 11/23/2020 SR 20208466111 - File Number 4787587 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF SIGHT SCIENCES, INC. Sight Sciences, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the ?Corporation?), DOE |
|
| July 8, 2021 |
Employment Agreement between Sight Sciences, Inc. and Paul Badawi, dated July 7, 2021 Exhibit 10.11 Employment Agreement This Employment Agreement (this ?Agreement?), dated as of July 7, 2021, is made by and between Sight Sciences, Inc., a Delaware corporation (together with any successor thereto, the ?Company?), and Paul Badawi (?Executive?) (collectively referred to herein as the ?Parties? or individually referred to as a ?Party?), and will become effective, if at all, upon the d |
|
| July 8, 2021 |
July 8, 2021 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| July 8, 2021 |
Employment Agreement between Sight Sciences, Inc. and David Badawi, M.D., dated July 7, 2021 Exhibit 10.14 Employment Agreement This Employment Agreement (this ?Agreement?), dated as of July 7, 2021, is made by and between Sight Sciences, Inc., a Delaware corporation (together with any successor thereto, the ?Company?), and David Badawi, M.D. (?Executive?) (collectively referred to herein as the ?Parties? or individually referred to as a ?Party?), and will become effective, if at all, upo |
|
| July 8, 2021 |
2021 Incentive Award Plan and form of option agreements thereunder Exhibit 10.2 SIGHT SCIENCES, INC. 2021 INCENTIVE AWARD PLAN ARTICLE I. PURPOSE The Plan?s purpose is to enhance the Company?s ability to attract, retain and motivate persons who make (or are expected to make) important contributions to the Company by providing these individuals with equity ownership opportunities. Capitalized terms used in the Plan are defined in Article XI. ARTICLE II. ELIGIBILIT |
|
| July 8, 2021 |
Third Amended and Restated Investors’ Rights Agreement, dated as of November 23, 2020, as amended Exhibit 4.1 SIGHT SCIENCES, INC. THIRD AMENDED AND RESTATED INVESTORS? RIGHTS AGREEMENT Dated as of November 23, 2020 TABLE OF CONTENTS Page 1. Registration Rights 1 1.1 Definitions. For purposes of this Agreement: 1 1.2 Request for Registration. 3 1.3 Company Registration. 5 1.4 Obligations of the Company 6 1.5 Information From Holder 8 1.6 Expenses of Registration 8 1.7 Delay of Registration 8 1 |
|
| July 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Sight Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 80-0625749 (State of incorporation or organization) (I.R.S. Employer Identification No.) 4040 Campbell Avenue, S |
|
| July 8, 2021 |
Non-Employee Director Compensation Program Exhibit 10.3 SIGHT SCIENCES, INC. NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM Non-employee members of the board of directors (the ?Board?) of Sight Sciences, Inc. (the ?Company?) shall receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this ?Program?). The cash and equity compensation described in this Program shall be paid or be made, as applicabl |
|
| July 8, 2021 |
Employment Agreement between Sight Sciences, Inc. and Sam Park, dated July 7, 2021 Exhibit 10.13 Employment Agreement This Employment Agreement (this ?Agreement?), dated as of July 7, 2021, is made by and between Sight Sciences, Inc., a Delaware corporation (together with any successor thereto, the ?Company?), and Sam Park (?Executive?) (collectively referred to herein as the ?Parties? or individually referred to as a ?Party?), and will become effective, if at all, upon the date |
|
| July 8, 2021 |
Specimen Stock Certificate evidencing the shares of common stock Exhibit 4.2 COMMON STOCK SHARES CUSIP 82657M 10 5 SEE REVERSE FOR CERTAIN DEFINITIONS INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE THIS CERTIFIES THAT IS THE RECORD HOLDER OF FULLY PAID AND NON-ASSESSABLE SHARES OF COMMON STOCK, $.001 PAR VALUE PER SHARE, OF SIGHT SCIENCES, INC. transferable on the books of the Corporation in person or by duly authorized attorney upon surrender of this cer |
|
| July 8, 2021 |
Sight Sciences, Inc. 2021 Employee Stock Purchase Plan Exhibit 10.4 SIGHT SCIENCES, INC. 2021 EMPLOYEE STOCK PURCHASE PLAN ARTICLE I. PURPOSE The purpose of this Plan is to assist Eligible Employees of the Company and its Designated Subsidiaries in acquiring a stock ownership interest in the Company. The Plan consists of two components: (i) the Section 423 Component and (ii) the Non-Section 423 Component. The Section 423 Component is intended to quali |
|
| July 8, 2021 |
As filed with the Securities and Exchange Commission on July 8, 2021 Table of Contents As filed with the Securities and Exchange Commission on July 8, 2021 Registration No. |
|
| July 8, 2021 |
Form of Restated Certificate of Incorporation of the Registrant Exhibit 3.3 RESTATED CERTIFICATE OF INCORPORATION OF SIGHT SCIENCES, INC. The name of the corporation is Sight Sciences, Inc. The corporation was originally incorporated by the filing of its original Certificate of Incorporation with the Secretary of State of the State of Delaware on February 10, 2010. This Restated Certificate of Incorporation of the corporation, which restates and integrates and |
|
| July 8, 2021 |
Exhibit 3.4 AMENDED AND RESTATED BYLAWS OF SIGHT SCIENCES, INC. (a Delaware corporation) TABLE OF CONTENTS Page ARTICLE I - CORPORATE OFFICES 1 1.1 REGISTERED OFFICE 1 1.2 OTHER OFFICES 1 ARTICLE II - MEETINGS OF STOCKHOLDERS 1 2.1 PLACE OF MEETINGS 1 2.2 ANNUAL MEETING 1 2.3 SPECIAL MEETING 1 2.4 ADVANCE NOTICE PROCEDURES FOR BUSINESS BROUGHT BEFORE A MEETING 2 2.5 ADVANCE NOTICE PROCEDURES FOR N |
|
| July 1, 2021 |
CONFIDENTIAL TREATMENT HAS BEEN REQUESTED BY SIGHT SCIENCES, INC. 200 Clarendon Street Boston, Massachusetts 02116 Tel: +1.617.948.6000 Fax: +1.617.948.6001 www.lw.com July 1, 2021 FOIA CONFIDENTIAL TREATMENT REQUEST UNDER 17 C.F.R. ?200.83 The entity requesting confidential treatment is: FIRM / AFFILIATE OFFICES Beijing Moscow Boston Munich Brussels New York Century City Orange County Chicago Paris Dubai Riyadh D?sseldorf San Diego Frankfurt San Francisco Hambu |
|
| June 23, 2021 |
Subsidiaries of the Registrant EX-21.1 12 d90195dex211.htm EX-21.1 Exhibit 21.1 Subsidiaries of Sight Sciences, Inc. Legal Name of Subsidiary Jurisdiction of Organization Sight Sciences UK, Ltd. United Kingdom |
|
| June 23, 2021 |
Power of Attorney (included on signature page) Table of Contents As filed with the Securities and Exchange Commission on June 23, 2021 Registration No. |
|
| June 23, 2021 |
Third Amended and Restated Investors’ Rights Agreement, dated as of November 23, 2020 Exhibit 4.1 SIGHT SCIENCES, INC. THIRD AMENDED AND RESTATED INVESTORS? RIGHTS AGREEMENT Dated as of November 23, 2020 TABLE OF CONTENTS Page 1. Registration Rights 1 1.1 Definitions. For purposes of this Agreement: 1 1.2 Request for Registration. 3 1.3 Company Registration. 5 1.4 Obligations of the Company 6 1.5 Information From Holder 8 1.6 Expenses of Registration 8 1.7 Delay of Registration 8 1 |
|
| June 23, 2021 |
Certificate of Incorporation of the Registrant, as amended (currently in effect) Exhibit 3.1 State of Delaware Secretary of State Division of Corporations Delivered 08:08 AM 11/23/2020 FILED 08:08 AM 11/23/2020 SR 20208466111 - File Number 4787587 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF SIGHT SCIENCES, INC. Sight Sciences, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the ?Corporation?), DOE |
|
| June 23, 2021 |
Form of Warrant to Purchase Stock Exhibit 4.3 Sight Sciences, Inc. Schedule of Holders of Warrants Number of Class of Warrant Holder Name Shares Stock Price Issue Date MidCap Funding XXVII Trust 3,162 C $ 9.4868 2/4/20191 MidCap Funding XXVII Trust 527 C $ 9.4868 2/9/20192 MidCap Funding XXVII Trust 300,000 F $ 21.8779 11/23/2020 MidCap Funding XXVIII Trust 22,136 C $ 9.4868 1/25/2019 MidCap Funding XXVIII Trust 3,689 C $ 9.4868 1 |
|
| June 23, 2021 |
Exhibit 3.2 BYLAWS OF SIGHT SCIENCES, INC. a Delaware corporation TABLE OF CONTENTS Page ARTICLE 1 OFFICES 1 Section 1.1 Registered Office 1 Section 1.2 Other Offices 1 ARTICLE 2 STOCKHOLDERS? MEETINGS 1 Section 2.1 Place of Meetings 1 Section 2.2 Annual Meetings 2 Section 2.3 Special Meetings 2 Section 2.4 Notice of Meetings 2 Section 2.5 Quorum and Voting 3 Section 2.6 Voting Rights 4 Section 2. |
|
| June 23, 2021 |
Exhibit 10.9 Execution Version AMENDED AND RESTATED CREDIT AND SECURITY AGREEMENT (REVOLVING LOAN) dated as of November 23, 2020 by and among SIGHT SCIENCES, INC., and any additional borrower that hereafter becomes party hereto, each as Borrower, and collectively as Borrowers, and MIDCAP FUNDING IV TRUST, as Agent and as a Lender, and THE ADDITIONAL LENDERS FROM TIME TO TIME PARTY HERETO TABLE OF |
|
| June 23, 2021 |
Sublease, dated as of September 17, 2019, between the Registrant and Cellular Research, Inc. Exhibit 10.6 EXECUTION VERSION SUBLEASE THIS SUBLEASE (?Sublease?), dated as of September 17, 2019, is made by and between CELLULAR RESEARCH, INC., a Delaware corporation (a wholly owned subsidiary of Becton, Dickinson and Company, a New Jersey corporation) (?Sublessor?) and SIGHT SCIENCES, INC., a Delaware corporation (?Sublessee?) (Sublessor and Sublessee, collectively the ?Parties,? or individu |
|
| June 23, 2021 |
Exhibit 10.1 SIGHT SCIENCES, INC. 2011 STOCK INCENTIVE PLAN 1. Purposes of the Plan. The purposes of this Plan are to attract and retain the best available personnel, to provide additional incentives to Employees, Directors and Consultants and to promote the success of the Company?s business. 2. Definitions. The following definitions shall apply as used herein and in the individual Award Agreement |
|
| June 23, 2021 |
Exhibit 10.8 Execution Version AMENDED AND RESTATED CREDIT AND SECURITY AGREEMENT (TERM LOAN) dated as of November 23, 2020 by and among SIGHT SCIENCES, INC., and any additional borrower that hereafter becomes party hereto, each as Borrower, and collectively as Borrowers, and MIDCAP FINANCIAL TRUST, as Agent and as a Lender, and THE ADDITIONAL LENDERS FROM TIME TO TIME PARTY HERETO TABLE OF CONTEN |
|
| June 23, 2021 |
Multi-Tenant Space Lease between Sight Sciences and Deerfield Campbell, LLC, dated February 5, 2021. Exhibit 10.7 MULTI-TENANT SPACE LEASE (?NNN?) LANDLORD : DEERFIELD CAMPBELL LLC, a California limited liability company TENANT : SIGHT SCIENCES, INC., a Delaware corporation REFERENCE DATE : February 5, 2021 SUBJECT PROPERTY : 4040 Campbell Avenue Suites 100 and 120 Menlo Park, California (San Mateo County) TABLE OF CONTENTS ARTICLE 1. DEFINITIONS 1.1 Commencement Date 1 1.2 Lease Term 1 1.3 Prope |
|
| June 23, 2021 |
Exhibit 10.10 SUPPLY AGREEMENT This Supply Agreement (?Agreement?) is made effective as of January 14, 2021 (?Effective Date?) between Sight Sciences, Inc., a Delaware corporation with its principal office and place of business at 4040 Campbell Avenue, Suite 100, Menlo Park, California 94025 (?Buyer?), and Peter?s Technology (Suzhou) CO., LTD., a Suzhou, Jiangsu Province corporation, with its prin |
|
| May 24, 2021 |
Exhibit 10.8 Execution Version AMENDED AND RESTATED CREDIT AND SECURITY AGREEMENT (TERM LOAN) dated as of November 23, 2020 by and among SIGHT SCIENCES, INC., and any additional borrower that hereafter becomes party hereto, each as Borrower, and collectively as Borrowers, and MIDCAP FINANCIAL TRUST, as Agent and as a Lender, and THE ADDITIONAL LENDERS FROM TIME TO TIME PARTY HERETO TABLE OF CONTEN |
|
| May 24, 2021 |
Exhibit 10.10 SUPPLY AGREEMENT This Supply Agreement (?Agreement?) is made effective as of January 14, 2021 (?Effective Date?) between Sight Sciences, Inc., a Delaware corporation with its principal office and place of business at 4040 Campbell Avenue, Suite 100, Menlo Park, California 94025 (?Buyer?), and Peter?s Technology (Suzhou) CO., LTD., a Suzhou, Jiangsu Province corporation, with its prin |
|
| May 24, 2021 |
Exhibit 4.3 Sight Sciences, Inc. Schedule of Holders of Warrants Number of Class of Warrant Holder Name Shares Stock Price Issue Date MidCap Funding XXVII Trust 3,162 C $ 9.4868 2/4/20191 MidCap Funding XXVII Trust 527 C $ 9.4868 2/9/20192 MidCap Funding XXVII Trust 300,000 F $ 21.8779 11/23/2020 MidCap Funding XXVIII Trust 22,136 C $ 9.4868 1/25/2019 MidCap Funding XXVIII Trust 3,689 C $ 9.4868 1 |
|
| May 24, 2021 |
Exhibit 10.6 EXECUTION VERSION SUBLEASE THIS SUBLEASE (?Sublease?), dated as of September 17, 2019, is made by and between CELLULAR RESEARCH, INC., a Delaware corporation (a wholly owned subsidiary of Becton, Dickinson and Company, a New Jersey corporation) (?Sublessor?) and SIGHT SCIENCES, INC., a Delaware corporation (?Sublessee?) (Sublessor and Sublessee, collectively the ?Parties,? or individu |
|
| May 24, 2021 |
Exhibit 21.1 Subsidiaries of Sight Sciences, Inc. Legal Name of Subsidiary Jurisdiction of Organization Sight Sciences UK, Ltd. United Kingdom |
|
| May 24, 2021 |
BYLAWS SIGHT SCIENCES, INC. a Delaware corporation Exhibit 3.2 BYLAWS OF SIGHT SCIENCES, INC. a Delaware corporation TABLE OF CONTENTS Page ARTICLE 1 OFFICES 1 Section 1.1 Registered Office 1 Section 1.2 Other Offices 1 ARTICLE 2 STOCKHOLDERS? MEETINGS 1 Section 2.1 Place of Meetings 1 Section 2.2 Annual Meetings 2 Section 2.3 Special Meetings 2 Section 2.4 Notice of Meetings 2 Section 2.5 Quorum and Voting 3 Section 2.6 Voting Rights 4 Section 2. |
|
| May 24, 2021 |
As confidentially submitted to the Securities and Exchange Commission on May 24, 2021 DRS/A 1 filename1.htm Table of Contents As confidentially submitted to the Securities and Exchange Commission on May 24, 2021 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SIGHT SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 3841 80-0625749 (State or othe |
|
| May 24, 2021 |
200 Clarendon Street Boston, Massachusetts 02116 Tel: +1.617.948.6000 Fax: +1.617.948.6001 www.lw.com FIRM / AFFILIATE OFFICES Beijing Moscow Boston Munich Brussels New York Century City Orange County Chicago Paris Dubai Riyadh May 24, 2021 D?sseldorf San Diego Frankfurt San Francisco VIA EDGAR Hamburg Seoul Hong Kong Shanghai United States Securities and Exchange Commission Houston Silicon Valley |
|
| May 24, 2021 |
Exhibit 4.1 SIGHT SCIENCES, INC. THIRD AMENDED AND RESTATED INVESTORS? RIGHTS AGREEMENT Dated as of November 23, 2020 TABLE OF CONTENTS Page 1. Registration Rights 1 1.1 Definitions. For purposes of this Agreement: 1 1.2 Request for Registration. 3 1.3 Company Registration. 5 1.4 Obligations of the Company 6 1.5 Information From Holder 8 1.6 Expenses of Registration 8 1.7 Delay of Registration 8 1 |
|
| May 24, 2021 |
Exhibit 3.1 State of Delaware Secretary of State Division of Corporations Delivered 08:08 AM 11/23/2020 FILED 08:08 AM 11/23/2020 SR 20208466111 - File Number 4787587 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF SIGHT SCIENCES, INC. Sight Sciences, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the ?Corporation?), DOE |
|
| May 24, 2021 |
Exhibit 10.9 Execution Version AMENDED AND RESTATED CREDIT AND SECURITY AGREEMENT (REVOLVING LOAN) dated as of November 23, 2020 by and among SIGHT SCIENCES, INC., and any additional borrower that hereafter becomes party hereto, each as Borrower, and collectively as Borrowers, and MIDCAP FUNDING IV TRUST, as Agent and as a Lender, and THE ADDITIONAL LENDERS FROM TIME TO TIME PARTY HERETO TABLE OF |
|
| May 24, 2021 |
Exhibit 10.7 MULTI-TENANT SPACE LEASE (?NNN?) LANDLORD : DEERFIELD CAMPBELL LLC, a California limited liability company TENANT : SIGHT SCIENCES, INC., a Delaware corporation REFERENCE DATE : February 5, 2021 SUBJECT PROPERTY : 4040 Campbell Avenue Suites 100 and 120 Menlo Park, California (San Mateo County) TABLE OF CONTENTS ARTICLE 1. DEFINITIONS 1.1 Commencement Date 1 1.2 Lease Term 1 1.3 Prope |
|
| April 12, 2021 |
As confidentially submitted to the Securities and Exchange Commission on April 9, 2021 Table of Contents As confidentially submitted to the Securities and Exchange Commission on April 9, 2021 Registration No. |
